SCPS
Scopus BioPharma Inc.
Set alert
- YTD
- 0.00%
- 1 year
- +33.33%
- Open
- 0.0004
- Prev close
- 0.0004
- Mkt cap
- 16.83K
- Vol
- 47.08K
- Avg vol
- 3.55K
- EPS
- -0.41
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0004
- High
- 0.0004
- Forward P/E
- -0.07
- Beta
- 1.16
- Short ratio
- 0.22
- Inst. own
- 2.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.1921
- 200-d avg
- 0.354155
- 1y target
- 12.00
Key statistics
- Market cap
- 1.93M
- Enterprise value
- 1.61M
- Trailing P/E
- 0.00
- Forward P/E
- -0.07
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -1.51
- Beta
- 1.16
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -6.46M
- Total cash
- 310.82K
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 21.09M
- Short % of float
- 0.25%
- 50-day average
- 0.1921
- 200-day average
- 0.354155
Analyst view
Consensus: buy
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 16, 2021 | Benchmark | init | — | Speculative Buy |
About Scopus BioPharma Inc.
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- scopusbiopharma.com
News
- Contrasting Scopus BioPharma (NASDAQ:SCPS) & MorphoSys (NASDAQ:MOR)
- Scopus BioPharma's Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer
- Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
- Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
- Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
- Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session
- Stocks That Hit 52-Week Lows On Wednesday
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Wednesday
- Stocks That Hit 52-Week Lows On Wednesday
Your note
Sign in to keep a note on SCPS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GIBSON ROBERT J | Officer and Director | Purchase | Feb 24, 2021 | 300 |
| GREENSPAN IRA SCOTT | Officer, Director and Beneficial Owner | Purchase | Aug 26, 2021 | 0 |
| LAMSTEIN JOSHUA R | Chairman of the Board | Purchase | Aug 26, 2021 | 119,997 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 1.03% | 217,078 | 19.86K | Sep 29, 2022 |
| M&R Capital Management, Inc. | 0.36% | 76,819 | 7.03K | Dec 30, 2022 |
| Renaissance Technologies, LLC | 0.29% | 61,104 | 5.59K | Sep 29, 2022 |
| Tower Research Capital LLC (TRC) | 0.13% | 26,533 | 2.43K | Sep 29, 2022 |
| State Street Corporation | 0.10% | 20,729 | 1.90K | Sep 29, 2022 |
| HRT Financial LP | 0.07% | 14,353 | 1.31K | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.95% | 200,928 | 18.38K | Nov 29, 2022 |
| Fidelity Series Total Market Index Fund | 0.06% | 13,273 | 1.21K | Nov 29, 2022 |